People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available

In people with HIV who have belly fat and are on medication to control the virus, changes in IGF-1 levels from tesamorelin treatment did not relate to changes in thinking skills or waist size. This finding is from the abstract summary - full study details were not available

Changes in a growth hormone-related factor didn't match changes in muscle density or size in people with HIV and belly fat taking tesamorelin.

In people with HIV and belly fat who responded to tesamorelin, muscle density changes were linked to belly fat loss but not to changes in a growth-related hormone.

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had a waist size that was about 2.7 centimeters smaller on average compared to those who didn't, and this difference was statistically significant. This finding is from the abstract summary - full study details were not available

For people with HIV taking tesamorelin, changes in their growth hormone levels didn't match changes in their trunk muscle thickness or size.